[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2882261B1 - Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 - Google Patents

Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2

Info

Publication number
FR2882261B1
FR2882261B1 FR0501861A FR0501861A FR2882261B1 FR 2882261 B1 FR2882261 B1 FR 2882261B1 FR 0501861 A FR0501861 A FR 0501861A FR 0501861 A FR0501861 A FR 0501861A FR 2882261 B1 FR2882261 B1 FR 2882261B1
Authority
FR
France
Prior art keywords
diabetes
prevention
preparation
treatment
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0501861A
Other languages
English (en)
Other versions
FR2882261A1 (fr
Inventor
Corinne Hanotin
Pierre Rosenzweig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to FR0501861A priority Critical patent/FR2882261B1/fr
Priority to FR0504942A priority patent/FR2882264A1/fr
Priority to FR0505228A priority patent/FR2882265B1/fr
Priority to AU2006215444A priority patent/AU2006215444A1/en
Priority to JP2007555669A priority patent/JP2008530189A/ja
Priority to UY29386A priority patent/UY29386A1/es
Priority to TW095105631A priority patent/TW200640457A/zh
Priority to CA002597245A priority patent/CA2597245A1/fr
Priority to KR1020077018993A priority patent/KR20070104913A/ko
Priority to ZA200707012A priority patent/ZA200707012B/xx
Priority to CNA2006800052531A priority patent/CN101119727A/zh
Priority to PCT/FR2006/000376 priority patent/WO2006087481A1/fr
Priority to EP06709344A priority patent/EP1853264A1/fr
Priority to EA200701781A priority patent/EA011618B1/ru
Priority to MX2007009996A priority patent/MX2007009996A/es
Priority to BRPI0608183-5A priority patent/BRPI0608183A2/pt
Priority to ARP060100611A priority patent/AR053812A1/es
Publication of FR2882261A1 publication Critical patent/FR2882261A1/fr
Priority to TNP2007000297A priority patent/TNSN07297A1/en
Priority to US11/832,865 priority patent/US20080015229A1/en
Priority to CR9293A priority patent/CR9293A/es
Priority to IL185401A priority patent/IL185401A0/en
Priority to MA30158A priority patent/MA29262B1/fr
Priority to NO20074767A priority patent/NO20074767L/no
Application granted granted Critical
Publication of FR2882261B1 publication Critical patent/FR2882261B1/fr
Priority to US12/402,988 priority patent/US20090197917A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0501861A 2005-02-21 2005-02-21 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 Expired - Fee Related FR2882261B1 (fr)

Priority Applications (24)

Application Number Priority Date Filing Date Title
FR0501861A FR2882261B1 (fr) 2005-02-21 2005-02-21 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0504942A FR2882264A1 (fr) 2005-02-21 2005-05-12 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0505228A FR2882265B1 (fr) 2005-02-21 2005-05-23 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2.
EA200701781A EA011618B1 (ru) 2005-02-21 2006-02-20 Применение римонабанта для получения лекарственных средств, пригодных для профилактики и лечения диабета типа 2
UY29386A UY29386A1 (es) 2005-02-21 2006-02-20 Utilizción de rimonabant para la preparación de medicamentos útiles en la prevención y el tratamiento de la diabetes de tipo2.
TW095105631A TW200640457A (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes
CA002597245A CA2597245A1 (fr) 2005-02-21 2006-02-20 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
KR1020077018993A KR20070104913A (ko) 2005-02-21 2006-02-20 2형 당뇨병의 예방 및 치료에 사용될 수 있는 약제의제조를 위한 리모나반트의 용도
ZA200707012A ZA200707012B (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
CNA2006800052531A CN101119727A (zh) 2005-02-21 2006-02-20 利莫那班在制备用于预防和治疗2型糖尿病的药物中的用途
PCT/FR2006/000376 WO2006087481A1 (fr) 2005-02-21 2006-02-20 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
EP06709344A EP1853264A1 (fr) 2005-02-21 2006-02-20 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
AU2006215444A AU2006215444A1 (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
MX2007009996A MX2007009996A (es) 2005-02-21 2006-02-20 Utilizacion de rimonabant para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la diabetes de tipo 2.
BRPI0608183-5A BRPI0608183A2 (pt) 2005-02-21 2006-02-20 utilização do rimonabante para o preparo de medicamentos úteis na prevenção e no tratamento do diabetes do tipo 2
JP2007555669A JP2008530189A (ja) 2005-02-21 2006-02-20 ２型糖尿病の防止および処置において使用することができる医薬品を調製するためのリモナバントの使用
ARP060100611A AR053812A1 (es) 2005-02-21 2006-02-21 Utilizacion de rimonabant para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la diabetes de tipo2
TNP2007000297A TNSN07297A1 (en) 2005-02-21 2007-07-31 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
US11/832,865 US20080015229A1 (en) 2005-02-21 2007-08-02 Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes
CR9293A CR9293A (es) 2005-02-21 2007-08-07 Utilizacion de rimonabant para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la diabetes de tipo 2
IL185401A IL185401A0 (en) 2005-02-21 2007-08-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
MA30158A MA29262B1 (fr) 2005-02-21 2007-08-23 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
NO20074767A NO20074767L (no) 2005-02-21 2007-09-18 Anvendelse av rimonabant for fremstilling av medikamenter som kan anvendes i forebygging og behandling av type 2 diabetes
US12/402,988 US20090197917A1 (en) 2005-02-21 2009-03-12 Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501861A FR2882261B1 (fr) 2005-02-21 2005-02-21 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2

Publications (2)

Publication Number Publication Date
FR2882261A1 FR2882261A1 (fr) 2006-08-25
FR2882261B1 true FR2882261B1 (fr) 2009-02-06

Family

ID=34954874

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0501861A Expired - Fee Related FR2882261B1 (fr) 2005-02-21 2005-02-21 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2

Country Status (3)

Country Link
CN (1) CN101119727A (fr)
FR (1) FR2882261B1 (fr)
ZA (1) ZA200707012B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114452831B (zh) * 2022-01-24 2023-04-25 中南大学湘雅医院 一种表面涂覆体外循环改性膜及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity

Also Published As

Publication number Publication date
CN101119727A (zh) 2008-02-06
ZA200707012B (en) 2008-12-31
FR2882261A1 (fr) 2006-08-25

Similar Documents

Publication Publication Date Title
EP2047853A4 (fr) Utilisation de stéroïde marin dans la préparation d'un médicament pour le traitement des lésions neuronales
FR20C1066I1 (fr) Pièges à gdf pour l'utilisation dans le traitment de l'anémie
EP1789075A4 (fr) Substances ameliorant l'absorption destinees a l'administration de medicaments
FR2867778B1 (fr) Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
FR19C1005I2 (fr) Nano-corps ameliores (tm) pour le traitement des troubles lies a l'agregation
FR2869541B1 (fr) Utilisation d'une composition comprenant du d-mannoheptulose et/ou du perseitol dans le traitement et la prevention des maladies liees a une modification de l'immunite innee
EP2255822A4 (fr) Utilisation de la section efficace d'alcaloïdes provenant de ramulus mori dans la préparation d'un agent hypoglycémiant
EP1799263A4 (fr) Reduction du stress du re dans le traitement de l'obesite et du diabete
FR15C0069I2 (fr) Formulation a usage topique d'ivermectine pour le traitement de conditions dermatologiques
EP1957077A4 (fr) Derives substitues de 4-amino-pyrrolotriazine utiles dans le traitement de troubles hyperproliferatifs et de maladies associees a l'angiogenese
EP1817003A4 (fr) Cristaux photoniques poreux pour l'administration oculaire de medicaments
EP1631269A4 (fr) Methodes et compositions destinees a l'administration de butanes catecholiques pour le traitement de l'obesite
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
EP1604664A4 (fr) Medicament pour la prevention et le traitement de l'arteriosclerose et de l'hypertension
MA29084B1 (fr) Derives d'indenyle et leur utilisation dans le traitement de troubles neurologiques
MA28844B1 (fr) Composition pharmaceutique comprenant de la drospirenone et de l'ethynylestradiol
EP2255816A4 (fr) Utilisation de composés extraits de momordica charantia l. dans la fabrication de médicaments destinés à la prévention et au traitement du diabète et de l'obésité
FR2887450B1 (fr) Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques
FR2917622B1 (fr) Utilisation d'un antagoniste par1 dans le traitement de la fibrillation atriale.
IL185300A0 (en) New pharmaceutical compositions useful in the treatment of parkinson's disease
EP1679070A4 (fr) Utilisation de l-butylphtalide dans la fabrication de medicaments destines a la prevention et au traitement de l'infarctus cerebral
FR2919187B1 (fr) Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie.
FR2882261B1 (fr) Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR2882265B1 (fr) Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2.
FR2882263B1 (fr) Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20101029